Technologies
Cancer represents a serious challenge to public health and the global economy, and its incidence continues to rise. In 2020, more than 19.3 million cases were reported, and this figure is estimated to reach 28.4 million by 2040, driven by population growth and ageing.
Oncobiomed Advanced Cell Technology S.p.A., based in Santiago, Chile, is a biotechnology company specialising in the development and technology transfer of cancer vaccines based on immunogenic lysates.. TAPCells® y LycellVax® han sido diseñadas como terapias para cáncer de colon, melanoma, cáncer de próstata y otros tipos de cáncer. Estas tecnologías ya han completado estudios clínicos de fase I o fase II y han mostrado superioridad respecto a otras terapias por su efectividad clínica de largo plazo, la ausencia de efectos adversos y su adaptación a la realidad económico-social de los países emergentes.
The global immunotherapy drug market was estimated at USD 284 billion in 2024 and is expected to reach around USD 1.3 trillion by 2033.In this context, Oncobiomed is valued at USD 32 million, and its technologies are estimated to reach projected sales of USD 6 billion for melanoma and USD 27 billion for prostate cancer.
The success of the immunotherapies developed by Oncobiomed has benefited more than 300 patients, whose clinical results have been published in scientific journals with global impact. The company has also obtained, logrando además la patents to commercialise its technologies in Chile, Australia, New Zealand, the United States, Mexico, Brazil and Israel..
Scientific publications
2025 - 2021
2024
Long-Term Survival and Immune Response Dynamics in Melanoma Patients Undergoing TAPCells-Based Vaccination Therapy.
2023
Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response.
2022
Haptoglobin Induces a Specific Proteomic Profile and a Mature-Associated Phenotype on Primary Human Monocyte-Derived Dendritic Cells.
2021
C-type lectin receptors MR and DC-SIGN are involved in recognition of hemocyanins, shaping their immunostimulatory effects on human dendritic cells.
2020 - 2018
2020
2019
Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell- Dependent Antitumor Immune Responses In Vitro.
2018
2018
2018
2013 - 2011
2013
Immunological and Clinical Outcomes of DC-Vaccinated Melanoma Patients Are Associated with Increased Th1/Th17 and Reduced Th3 Cytokine Responses.
2013
Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients.
2013
TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer.
2012
Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients.
2011
Heat-Shock Induction of Tumor-Derived Danger Signals Mediate Rapid Monocyte Differentiation into Clinically Effective Dendritic Cells.
2009 - 2005
2009
Prolonged Survival of Dendritic Cell–Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor B-Expressing T Cells.
2007
Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape.
2006
The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
2005
Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Dr. Salazar is a pioneer in Chile with this technique
Dr. Salazar is a pioneer in Chile with this technique. The vaccine is more than interesting because it gives the immune system the opportunity to recognise the tumour cells based on something that is native to the human body. That is different from what happens with conventional therapies, such as chemotherapy, which in many cases fail to get the immune system working again. If there is a chance of recovery, it is through these treatments.
Juan Carlos Roa
Everything was gone, there were no more tumors
The treatment lasted between March and June 2010. And it worked. First, they told me metastasis had been reduced and then, in September, the scanner showed there was no detectable metastasis. Everything had disappeared, there were no more tumours. I continued with controls every six months until 2014 and since then, I get controls once a year. I’m healthy.
Jaime Lagos
These have been my best years since I was diagnosed
In 2006, I was diagnosed with prostate cancer. After undergoing surgery in the United States and radiation therapy without achieving the expected results, I decided to contact Oncobiomed. Since then, I’ve been able to keep my prostate antigen levels under control safely. These have been my best years since I was diagnosed, as I’ve managed to extend my life without any side effects, unlike other traditional cancer therapies.
José Schiappacasse
I got the vaccine and went on with my normal life
In the midst of the pandemic, at the end of 2020, I was diagnosed with melanoma cancer. After having a tumour removed from my ankle, I contacted Oncobiomed to complement the procedures I was already receiving. The main advantage of this treatment is that there are no side effects and it is a personalised procedure. It is not something they did for the disease in general. They gave me the vaccine and I continued with my normal life, my hair never fell out, nothing.
Constanza Solís
Contact
Contact
Santiago, Chile
+56 9 7753 2325
